BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Booth L, West C, Hoff DV, Dent P. GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling. Front Oncol 2020;10:1331. [PMID: 32983965 DOI: 10.3389/fonc.2020.01331] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Choi J, Bordeaux ZA, Mckeel J, Nanni C, Sutaria N, Braun G, Davis C, Miller MN, Alphonse MP, Kwatra SG, West CE, Kwatra MM. GZ17-6.02 Inhibits the Growth of EGFRvIII+ Glioblastoma. IJMS 2022;23:4174. [DOI: 10.3390/ijms23084174] [Reference Citation Analysis]
2 Mirzaei S, Gholami MH, Hashemi F, Zabolian A, Farahani MV, Hushmandi K, Zarrabi A, Goldman A, Ashrafizadeh M, Orive G. Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects. Drug Discov Today 2021:S1359-6446(21)00428-1. [PMID: 34624510 DOI: 10.1016/j.drudis.2021.09.020] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Booth L, West C, Von Hoff D, Kirkwood JM, Dent P. GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells. Front Oncol 2021;11:656453. [PMID: 33898322 DOI: 10.3389/fonc.2021.656453] [Reference Citation Analysis]
4 Booth L, West C, Moore RP, Von Hoff D, Dent P. GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins. Front Oncol 2021;11:711043. [PMID: 34490108 DOI: 10.3389/fonc.2021.711043] [Reference Citation Analysis]
5 Booth L, West C, Moore RP, Von Hoff D, Dent P. GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells. Oncotarget 2022;13:92-104. [PMID: 35035775 DOI: 10.18632/oncotarget.28177] [Reference Citation Analysis]